Palisade Bio Inc Stock News

First Patient Dosed in Global Phase 2b ASCENTRA-UC Trial; Topline Results Expected in Q4 2027 FDA Clearance Received for Phase 2a ASCENTRA-CD Trial; Initiation of Enrollment Targeted for Q1 2027 New Clinical and Translational Data Presented at ACG and UEG Week 2026 Highlight PALI-2108's Targeted Profile $113.6 Million in Cash and Cash Equivalents as of September 30, 2026 Denver, CO, Nov. 10, 20...

PALI-2108 is an investigational, gut-activated, once-daily oral PDE4 inhibitor prodrug designed for sustained exposure and anti-inflammatory activity with the potential to improve tolerability

Five-patient Phase 1b Crohn's disease cohort showed a 47.5% reduction in mean endoscopic disease activity and a 58.8% reduction in mean fecal calprotectin after 14 days

Canadian clearance supports site activation and enrollment in the global study of once-daily oral PALI-2108 Primary efficacy results from approximately 204 patients with moderately to severely active ulcerative colitis expected in the second half of 2027 Denver, CO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceut...

ASCENTRA-CD expected to enroll approximately 60 patients with moderate to severe Crohn's disease First patient dosing targeted for Q1 2027; primary efficacy readout (Week 12 endoscopic response) targeted for Q1 2028 Phase 2 program builds on clinical experience in fibrostenotic Crohn's disease demonstrating targeted tissue exposure, PDE4 target engagement and encouraging endoscopic activity Den...

Management to participate in investor meetings on July 14-15 in Boston Denver, CO, July 10, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation oral PDE4 inhibitor prodrugs for inflammatory bowel disease, today announced that JD Finley, Chief Executive Officer, and Dr. Mitchell Jones, Pre...

ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe

Board strengthened with extensive biotechnology leadership, strategic transactions and capital markets expertise Company continues to build on PALI-2108 clinical progress as it advances toward Phase 2 development and additional key milestones Denver, CO, June 11, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company ...